トシリズマブ

Effective treatment of severe COVID-19 patients with tocilizumab.
 Xu X, et al.〔Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975〕（査読済み）


Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
 Somers EC, et al.〔Clin Infect Dis. 2020 Jul 11〕（査読済み）

Association between Early Treatment with Tocilizumab and Mortality among Critically Ill Patients with COVID-19
 Gupta S, et al.〔JAMA Intern Med. 2021 Jan 1;181(1):41-51〕（査読済み）

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial
 Hermine O, et al.〔JAMA Intern Med. 2021 Jan 1;181(1):32-40〕（査読済み）

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial (Research Letter)
 Mariette X, et al.〔JAMA Intern Med. 2021 May 24〕（査読済み）

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial
 Salvarani C, et al.〔JAMA Intern Med. 2021 Jan 1;181(1):24-31〕（査読済み）

Impact of tocilizumab administration on mortality in severe COVID-19
 Tsai A, et al.〔Sci Rep. 2020 Nov 5;10(1):19131〕（査読済み）

Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab
 Salvarani C, et al.〔Immunol Lett. 2020 Dec;228:122-128〕（査読済み）

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
 De Cáceres C, et al.〔Pharmacol Rep. 2020 Dec;72(6):1529-1537〕（査読済み）

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis
 Tleyjeh IM, et al.〔Clin Microbiol Infect. 2021 Feb;27(2):215-227〕（査読済み）

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
 Mady A, et al.〔Ann Med Surg (Lond). 2020 Dec;60:417-424〕（査読済み）

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort
 Corominas H, et al.〔Clin Immunol. 2021 Feb;223:108631〕（査読済み）

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
 Kaye AG, et al.〔PeerJ. 2020 Nov 2;8:e10322〕（査読済み）

Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety
 Hill JA, et al.〔J Med Virol. 2021 Apr;93(4):2270-2280〕（査読済み）

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
 Lewis TC, et al.〔Crit Care Explor. 2020 Nov 16;2(11):e0283〕（査読済み）

Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
 Ruiz-Antorán B, et al.〔Infect Dis Ther. 2020 Dec 6:1-16〕（査読済み）

Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia
 Salama C, et al.〔N Engl J Med. 2021 Jan 7;384(1):20-30〕（査読済み）

The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
 Kow CS, et al.〔Eur J Clin Pharmacol. 2021 Feb 2:1-6〕（査読済み）

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
 RECOVERY Collaborative Group, et al.〔medRxiv. 2021 Feb 11〕（査読前）

Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia
 Rosas IO, et al.〔N Engl J Med. 2021 Feb 25〕（査読済み）

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
 Soin AS, et al.〔The Lancet March 04, 2021 doi.org 10.1016 S2213-2600(21)00081-3〕（査読済み）

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
 Petrak RM, et al.〔Crit Care Explor. 2021 Mar 29;3(4):e0395〕（査読済み）

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
 RECOVERY Collaborative Group.〔Lancet. 2021 May 1;397(10285):1637-1645〕（査読済み）

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
 WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group〔JAMA. 2021 Jul 6:e2111330〕（査読済み）